Prelude Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Prelude Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,799	Closed	-$2.4M	–	1588
2023 Q4	$2.4M	Buy	40,799 +36,021	+754%	+$2.03M	0.16%	144
2023 Q3	$208K	Buy	+4,778	New	+$171K	0.01%	876
2020 Q4	–	Sell	-1,005	Closed	-$167K	–	2140
2020 Q3	$167K	Buy	+1,005	New	+$138K	0.01%	746
2020 Q1	–	Sell	-121	Closed	-$16K	–	2162
2019 Q4	$16K	Sell	121 -2,872	-96%	-$277K	﹤0.01%	1635
2019 Q3	$233K	Buy	+2,993	New	+$281K	0.01%	722
2018 Q4	–	Sell	-2,951	Closed	-$139K	–	2250
2018 Q3	$139K	Buy	+2,951	New	+$164K	0.01%	883
2016 Q4	–	Sell	-3,300	Closed	-$22K	–	1841
2016 Q3	$22K	Buy	+3,300	New	+$17.6K	﹤0.01%	1330

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's MRTX Position: Q1 2024 in Review

Prelude Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 40,799 shares — an estimated $2.4M sold.

Prelude Capital Management first reported a position in MRTX in Q3 2016 and held it in 7 quarters. The position peaked at $2.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Prelude Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Prelude Capital Management sold 40,799 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.4M.
Prelude Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
Prelude Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.4M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.